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injections, measured MAs decreased to 4.03 ± 0.66. In the un-
treated control group, the initial number of 3.36 ± 0.6 MAs re-
mained almost unchanged over 3–4 months (2.89 ± 0.57 MAs). 
Dynamic analysis showed that after ranibizumab treatment 
3.06 ± 0.5 new MAs appeared, while 5.09 ± 0.79 disappeared. 
In the control group, 2.11 ± 0.4 new MAs appeared and 2.61 ± 
0.48 disappeared. MA turnover was significantly higher with 
ranibizumab compared to the control group (8.15 ± 1.14 vs. 
4.72 ± 0.81, p < 0.001). Consistently, CRT decreased from 444 to 
330 μm in the ranibizumab group, while there was no change 
in the control group (291 vs. 288 μm).  Conclusion: The treat-
ment of macular edema using ranibizumab does not only re-
duce macular thickness, but also has an impact on the turnover 
of MAs in diabetic retinopathy. RetmarkerDR analysis showed 
that more pre-existent MAs disappeared than new MAs devel-
oped, and the absolute number of MAs also decreased. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Diabetic retinopathy is one of the leading causes of 
blindness in the western world and accounts for most cas-
es of legal blindness in the working age  [1] . The incidence 
 Key Words 
 Ranibizumab · Diabetic retinopathy · Progression · 
Microaneurysm turnover · Retmarker · Diabetic macular 
edema · Optomap · Automated fundus image analysis  
 Abstract 
 Purpose: To evaluate the influence of a ranibizumab treatment 
on microaneurysm (MA) turnover in diabetic retinopathy. 
 Methods: Sixty-nine eyes were included in this retrospective 
study. We compared a group of 33 eyes with ranibizumab 
treatment for diabetic macular edema to 36 eyes with nonpro-
liferative diabetic retinopathy only. Nonmydriatic ultra-wide-
field scanning laser ophthalmoscopy (Optomap) images were 
obtained at a mean 4.76 ± 1.69 days prior to the first ranibi-
zumab injection (baseline) and again 35.94 ± 2.44 days after the 
third consecutive injection in a 4-week interval. In untreated 
controls, images were obtained at baseline and 97.81 ± 3.16 
days thereafter. Images were analyzed using the RetmarkerDR 
software (Critical Health SA, Coimbra, Portugal), and the turn-
over of MAs was documented and analyzed. Thereafter, MA 
turnover was correlated with central retinal thickness (CRT) as 
assessed by OCT.  Results: At baseline, patients in the treatment 
group had 5.64 ± 0.75 MAs. One month after 3 ranibizumab 
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of blindness associated with diabetic retinopathy in 
 Germany was reported to be 0.7/100,000 person-years of 
observation in a recent study  [2] .
 Visual loss in patients with type 2 diabetes is common-
ly caused by diabetic macular edema  [3] .
 The Early Treatment Diabetic Retinopathy Study 
( ETDRS) has shown that a significant reduction of visual 
loss is achieved by focal photocoagulation of macular 
edema, although laser photocoagulation is not always 
beneficial  [4] . Alternative promising treatment options 
for center-involving diabetic macular edema are now 
available following the introduction of vascular endothe-
lial growth factor (VEGF) inhibitors such as bevacizumab 
and ranibizumab  [5–7] , with ranibizumab being the only 
treatment option with a label.
 Besides the potential risk of diabetic macular edema, 
patients with diabetic retinopathy reveal characteristic 
signs such as microaneurysms (MAs), dot hemorrhages, 
hard exudates as a sign of vascular permeability and oth-
er abnormalities of retinal vessels such as venous bead-
ing and intraretinal microvascular abnormalities  [8] . 
Recent studies have emphasized the turnover of MAs 
assessed by an automated analysis (RetmarkerDR) as a 
predictive factor for the progression to clinically signifi-
cant macular edema (CSME) and to identify patients be-
ing at risk to develop sight-threatening complications 
 [9, 10] .
 On the other hand, little is known about the turnover 
of MAs in patients who already developed center-involv-
ing diabetic macular edema and are being treated with 
an anti-VEGF drug such as ranibizumab. One may hy-
pothesize that the pharmacological treatment of center-
involving diabetic macular edema not only has an im-
pact on central retinal thickness (CRT) as measured by 
optical coherence tomography (OCT) and visual acuity, 
but also on the turnover of MAs, a hallmark of diabetic 
retinopathy.
 Therefore, the present study was conducted to com-
pare MA turnover in diabetic eyes with and without 
CSME and in the eyes with CSME receiving ranibizumab 
treatment in order to assess whether there is any associa-
tion between MA turnover and edema resolution as mea-
sured by OCT  [10] .
 Methods 
 Study Population and Setup 
 We retrospectively evaluated fundus images from patients in 
our diabetic retinopathy outpatient clinic. Two groups of pa-
tients were established: group 1 including patients with newly 
formed fovea-involving diabetic macular edema being sched-
uled for treatment with ranibizumab, and group 2 including pa-
tients with nonproliferative diabetic retinopathy as a control. 
The diagnosis in patients of groups 1 and 2 was established us-
ing slitlamp microscope examination with a 78-dpt lens (Volk, 
Mentor, Ohio, USA); in group 1 we additionally performed 
OCT and fluorescein angiography if necessary to confirm the 
presence of macular edema. Patients in the treatment group un-
derwent 3 consecutive injections of ranibizumab at a 4-week 
interval.
 A total of 69 eyes of 55 patients (33 treated and 36 untreated 
eyes) were recruited for the study. At each visit a complete bilat-
eral eye examination, including best-corrected visual acuity, 
slitlamp microscope examination and fundus examination using 
a 78-dpt lens, as well as measurement of intraocular pressure were 
performed. In addition, digital ultra-widefield scanning laser 
ophthalmoscopy (Optomap) images were taken at each visit. In 
the present study using RetmarkerDR, images 4.76 ± 1.69 days 
prior to the first ranibizumab injection (baseline) and 35.94 ± 2.44 
days after the third injection were analyzed in the treatment 
group. In the control group, a baseline image and a follow-up im-
age after 97.81 ± 3.16 days were chosen for automated analysis. 
OCT examinations were performed at baseline and at each fol-
low-up visit in the treatment group and 3–4 months thereafter in 
the control group. Fellow eyes of patients undergoing treatment 
with ranibizumab were not allowed to be included in the control 
group.
 Image Selection and Preparation for the RetmarkerDR 
Analysis 
 Only high-quality images centered on the macular area were 
retrospectively and consecutively selected. The images were 
cropped (the periphery outside the retinal arcades was removed) 
prior to the analysis and then analyzed with the RetmarkerDR soft-
ware as described previously  [10] .
 Retmarker Analysis 
 The RetmarkerDR software compares images of the same fun-
dus area at different time points and registers newly formed or 
disappeared MAs (red dots). For more detailed information, 
please refer to the work of Haritoglou et al.  [10]  and Ribeiro et al. 
 [11] .
 MA Turnover 
 For each patient, both in the treatment and control groups, the 
total number of MAs, the number of newly formed MAs and the 
number of MAs which had disappeared was documented by com-
paring the baseline with the last follow-up visit. The MA turnover 
over the period of review was calculated by adding the absolute 
value of disappeared and newly formed MAs comparing baseline 
images and images obtained at the last visit.
 Optical Coherence Tomography 
 All OCT examinations were performed with a Heidelberg En-
gineering Spectralis SD-OCT (Heidelberg Engineering, Heidel-
berg, Germany). An examination consisted of a volume scan of 49 
B scans with a distance between B scans of 118 μm. OCTs had to 
be correctly centered, and CRT was documented for both, the 




















   
   
   
   
   
   
   
   
   
   
   


























 Statistical Analysis 
 All data are shown as means ± SEM. All results were stored in 
an Excel work sheet and analyzed with SPSS 21 (IBM Deutschland 
GmbH, Ehningen, Germany).
 Results 
 Study Population 
 The study population consisted of 31 male and 24 fe-
male patients. The mean age was 63.0 years (SD ±12.1, 
range 40–86 years).
 MA Numbers 
 Comparing the difference of total numbers of MAs 
in the treatment and control group, we observed a sig-
nificant difference at baseline (mean 5.64 ± 0.75 vs. 
3.36  ± 0.6; p  < 0.05 comparing treatment vs. control; 
 fig. 1 ) but not at the follow-up visit comparing treated 
patients with and without CSME (mean 4.03 ± 0.66 vs. 
2.89 ± 0.57).
 Within the treatment group, the mean number of MAs 
significantly decreased from 5.64 ± 0.75 at baseline to 
4.03 ± 0.66 MAs 1–2 months after the third ranibizumab 
injection (p  < 0.05;  fig.  1 ). In the untreated group, the 
mean number of 3.36 ± 0.6 MAs at baseline remained sta-
tistically unchanged until 3–4 months later with 2.89 ± 
0.57 MAs being calculated ( fig. 1 ).
 In the treatment group, 3.06 ± 0.5 new MAs had ap-
peared at the follow-up, while 5.09 ± 0.79 had disap-
peared. In the control group, 2.11 ± 0.4 new MAs had 
appeared at the follow-up, and 2.61 ± 0.48 had disap-
peared. The calculated turnover for both groups differed 
significantly with 8.15 ± 1.14 under ranibizumab treat-
ment and 4.72 ± 0.81 in the untreated group ( fig. 2 ; p < 
0.05).
 The comparison of MA turnover values in patients 
with and without CSME revealed a median turnover of 3 
in the group without CSME (CRT <300 μm), compared 
to a value of 6 in the CSME group (CRT  ≥ 300 μm; p < 
0.05;  fig. 3 ).
 OCT Measurements 
 At baseline, the mean CRT was 444 ± 29 μm (ranging 
from 202 to 822 μm) in the treatment group and 291 ± 22 
μm (ranging from 180 to 723 μm) in the control group 
(p < 0.001). At the follow-up, CRT had decreased to 330 ± 
23 μm (ranging from 160 to 604 μm) in the treatment 
group (p < 0.01), while it remained unchanged at 288 ± 
18 μm in the untreated group ( fig. 4 ).
 Fig. 1. Mean total MAs in the treated and the control group and 
their changes over time are shown in absolute numbers. While 
there was a significant reduction in MA numbers in the treatment 
group (p < 0.05), there was no change in the control group between 
baseline and follow-up. 
Fig. 2. With 8.15 ± 1.14 under ranibizumab treatment, the calcu-
lated turnover was significantly higher compared to that in the 
control group (4.72 ± 0.81; p < 0.05).
 Fig. 3. Here, the MA turnover is shown between baseline and fol-
low-up, given as absolute numbers, for both the non-CSME and 
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 Looking at the change in CRT and in total MA number 
between baseline and follow-up, we found a significant 
correlation (p < 0.01). Moreover, in those cases where a 
reduction of macular edema was observed, the turnover 
was significantly higher than in those eyes in which mac-
ular edema increased CRT (p < 0.05).
 Discussion 
 The presence of MAs, intraretinal hemorrhages and 
signs of vascular permeability and capillary closure, i.e. 
hard exudates and cotton wool spots, characterizes non-
proliferative diabetic retinopathy.
 In general, it is important to monitor the progres-
sion of the disease in a specific patient and identify the 
individual risk of progression to sight-threatening com-
plications such as diabetic macular edema or prolifera-
tive diabetic retinopathy. Unfortunately, MAs in dia-
betic retinopathy do not just accumulate and thus re-
veal progression of the disease. They appear and 
disappear as red dots on fundus photographs, and a 
high turnover is a predictive sign for fast progression to 
vision-threatening complications such as diabetic mac-
ular edema  [10] .
 The evolution and progression of retinal changes are 
different from patient to patient, making it necessary to 
closely monitor the individual eye for signs of disease 
progression. An early detection of those changes allows 
for timely and adequate treatment and thus for the pre-
vention of irreversible functional loss.
 In 1986, Kohner and Sleightholm  [12] first described 
a correlation between MA counts and the severity of ear-
ly diabetic retinopathy. Others reported that leaking 
MAs are associated with retinal thickness in diabetic ret-
inopathy  [13] . In recent years, counting numbers of 
MAs at the posterior pole of the retina and the evalua-
tion of the dynamics in MA turnover, i.e. their appear-
ance and disappearance, have been established as a 
prognostic factor for worsening of diabetic retinopathy 
and development of diabetic macular edema  [7, 9, 11, 
14–17] .
 While previous investigators had to work with manu-
al methods, like blinded counting by two separate graders 
 [17] , an automated software is now available with the Ret-
markerDR, providing reproducible analysis without con-
founders like experience, fatigue etc. and allowing for 
noninvasive screening, as fundus photography is widely 
available and easy to use. Due to image coregistration, it 
automatically provides information about appearance 
and disappearance of MAs in defined retinal areas, thus 
providing the formation rate of new MAs compared to an 
earlier examination.
 Not only has there been data about the predictive val-
ue of MA turnover for retinopathy progression, but also 
about MA dynamics under therapy. Two groups reported 
a reduction of retinal thickness after photocoagulation, 
correlated with a decrease in numbers of leaking MAs  [18, 
19] . Yet, data about the influence of pharmacological 
treatment on MAs was missing. Now for the first time we 
present data for the behavior of MA turnover under ra-
nibizumab treatment.
 Ranibizumab has been available for the treatment of 
diabetic macular edema for a couple of years and has 
been shown to not only influence visual acuity and CRT, 
but also to reduce the severity of diabetic retinopathy, ac-
cording to the modified ETDRS score  [20] . Therefore, 
one may assume that this fact is also reflected in MA 
turnover. And indeed, in our study we found that the av-
erage total number of MAs is decreasing in the ranibi-
zumab group, whereas the number of total MAs remains 
unchanged over 3–4 months in the untreated group. 
Also, more MAs vanished in the treated group, resulting 
in a higher MA turnover in the treatment group when 
compared to controls.
 In previous trials investigating the role of automated 
fundus analyses in diabetic retinopathy, a higher MA 
turnover was found to be a predictive factor for the devel-
opment of diabetic macular edema  [10] . Of note this ob-
servation was made in patients not undergoing any phar-
macological treatment such as anti-VEGF therapy. How-
 Fig. 4. While the mean CRT significantly differed between both 
groups at baseline (444 ± 29 vs. 291 ± 22 μm in controls; p < 0.001), 
CRT significantly decreased after treatment (p < 0.01) to a similar 





















































   
   
   
   
   
   
   
   
   
   
   


























ever, in line with this previous report, the MA turnover in 
the present study was higher in patients with CSME com-
pared to patients without CSME. In addition, the number 
of MAs was significantly higher in patients with macular 
edema compared to patients without macular edema.
 In the present study, we showed that the intravitreal 
injection of ranibizumab resulted in a decrease in the 
number of MAs with an increased turnover of MAs with 
more MAs disappearing than appearing. In other words, 
in eyes with diabetic macular edema, anti-VEGF treat-
ment resulted in an attenuation of diabetic fundus 
changes and an alignment of the fundus changes be-
tween eyes undergoing anti-VEGF treatment for diabet-
ic macular edema and eyes without diabetic macular 
edema. Therefore, one may assume that a high MA 
turnover not only stands for a higher risk for developing 
CSME and worsening of diabetic retinopathy in eyes 
without diabetic macular edema, but also for an in-
creased dynamic of the observed fundus changes in the 
context of intravitreal pharmacological therapy once 
macular edema has occurred. This finding might serve 
as a quantification of the treatment response in the fu-
ture, and it will be very interesting to investigate poten-
tial correlations with other parameters such as a de-
crease in CRT measured by optical coherence tomogra-
phy in a larger group of patients. As a preliminary result 
in this context, we were able to show that the changes in 
total number of MAs and MA turnover were accompa-
nied by a decrease in macular thickness under ranibi-
zumab treatment in our patients.
 Of course one may argue that a comparison of patients 
with nonproliferative diabetic retinopathy, with and 
without macular edema, as done in the present study, is 
critical. The aim of this investigation was to analyze the 
effect of an anti-VEGF treatment on MA turnover. As a 
control we chose a group of patients in whom one may 
not expect fundus changes over the period of review. This 
approach had the following reasons: first, this is a retro-
spective study with certain limitations due to study de-
sign, such as a lack of randomization; second, we could 
not withhold an effective treatment from patients and in-
clude patients with diabetic macular edema in an untreat-
ed control group.
 With the RetmarkerDR automated fundus analysis, 
additional insights could be presented on the effects of 
ranibizumab treatment. Not only an absolute reduction 
of the number of MAs could be shown, but also by dy-
namic analysis a higher decrease in new MAs was 
found. Those promising findings not only help to better 
understand the disease and dynamics, but might also 
serve as an additional quantification of the treatment 
response in the future. This might add to CRT as we 
move more and more towards response-driven treat-
ment schemes.
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